| Dr Donald Mario Sesso, DO | |
|
60 W Germantown Pike, Norristown, PA 19401-1565 | |
| (610) 279-7878 | |
| (610) 279-4725 |
| Full Name | Dr Donald Mario Sesso |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 25 Years |
| Location | 60 W Germantown Pike, Norristown, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558437566 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207YX0905X | Otolaryngology - Otolaryngology/facial Plastic Surgery | OS012066 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Einstein Medical Center Montgomery | East norriton, PA | Hospital |
| Chestnut Hill Hospital | Philadelphia, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Berger Henry Ent Specialty Group Pc | 2365344579 | 9 |
| Rehabclinics Spt Inc | 7113834102 | 298 |
News Archive
Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company's second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.
Whether chemotherapy is given before or after breast-conserving therapy (BCT) does not have an impact on long-term local-regional outcomes, suggesting treatment success is due more to biologic factors than chemotherapy timing, according to a study by researchers at The University of Texas MD Anderson Cancer Center.
Among the most deadly killers in the area of cancer, breast cancer is also extremely difficult to treat, once it has spread to the bones. Not only does it metastasize rapidly, but it comprises a variety of cell types and also depends on the input from many other non-breast cells during the initiation, growth and spread of the cancer. This complexity makes it more difficult to develop targeted therapies in this condition.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Ameritox, the nation's leader in pain medication monitoring, announced today the presentation of a peer-reviewed scientific poster titled "Patterns of Drug Use in the Older Chronic Pain Population" at the American Pain Society Annual Meeting.
› Verified 7 days ago
| Entity Name | Berger Henry Ent Specialty Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437220050 PECOS PAC ID: 2365344579 Enrollment ID: O20040127000059 |
News Archive
Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company's second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.
Whether chemotherapy is given before or after breast-conserving therapy (BCT) does not have an impact on long-term local-regional outcomes, suggesting treatment success is due more to biologic factors than chemotherapy timing, according to a study by researchers at The University of Texas MD Anderson Cancer Center.
Among the most deadly killers in the area of cancer, breast cancer is also extremely difficult to treat, once it has spread to the bones. Not only does it metastasize rapidly, but it comprises a variety of cell types and also depends on the input from many other non-breast cells during the initiation, growth and spread of the cancer. This complexity makes it more difficult to develop targeted therapies in this condition.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Ameritox, the nation's leader in pain medication monitoring, announced today the presentation of a peer-reviewed scientific poster titled "Patterns of Drug Use in the Older Chronic Pain Population" at the American Pain Society Annual Meeting.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Donald Mario Sesso, DO 60 W Germantown Pike, Norristown, PA 19401-1565 Ph: (610) 279-7878 | Dr Donald Mario Sesso, DO 60 W Germantown Pike, Norristown, PA 19401-1565 Ph: (610) 279-7878 |
News Archive
Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company's second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.
Whether chemotherapy is given before or after breast-conserving therapy (BCT) does not have an impact on long-term local-regional outcomes, suggesting treatment success is due more to biologic factors than chemotherapy timing, according to a study by researchers at The University of Texas MD Anderson Cancer Center.
Among the most deadly killers in the area of cancer, breast cancer is also extremely difficult to treat, once it has spread to the bones. Not only does it metastasize rapidly, but it comprises a variety of cell types and also depends on the input from many other non-breast cells during the initiation, growth and spread of the cancer. This complexity makes it more difficult to develop targeted therapies in this condition.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Ameritox, the nation's leader in pain medication monitoring, announced today the presentation of a peer-reviewed scientific poster titled "Patterns of Drug Use in the Older Chronic Pain Population" at the American Pain Society Annual Meeting.
› Verified 7 days ago
Warren H Zager, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 306 W Logan St, Norristown, PA 19401 Phone: 610-275-6153 Fax: 610-278-7709 | |
Dr. Todd C Morehouse, DO Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 60 West Germantown Pike, Norristown, PA 19401 Phone: 610-279-1414 Fax: 610-279-4725 | |
Dr. Marta T Becker, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 60 W Germantown Pike, Norristown, PA 19401 Phone: 610-279-1414 Fax: 610-279-4725 | |
Dr. Staci L Levick, Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 60 W Germantown Pike, Norristown, PA 19401 Phone: 610-279-1414 Fax: 610-279-4725 | |
Dr. Alan S Berger, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 60 W Germantown Pike, Norristown, PA 19401 Phone: 610-279-7878 Fax: 610-279-1680 | |
Alan Michael Miller, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 306 W Logan St, Norristown, PA 19401 Phone: 610-275-6153 Fax: 610-278-7709 |